Kura Oncology, Inc., founded in 2014 and headquartered in the United States, is a leading player in the Biotechnology and Pharmaceutical sectors. The company is committed to its mission: "Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives." By leveraging its extensive expertise in precision oncology, Kura Oncology is working to unravel the complexities of treatment resistance to develop cutting-edge therapies.
The company is currently commercializing KOMZIFTI™ (ziftomenib), an FDA-approved oral menin inhibitor designed for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Their strategy focuses on creating innovative combination regimens aimed at maximizing clinical outcomes.
In its latest financial milestone, Kura Oncology secured a $150.00M private placement investment on 01 January 2024 from prominent investors EcoR1 Capital and Suvretta Capital Management. This infusion underscores investor confidence in the company’s pioneering efforts in menin and farnesyl transferase inhibition.